American Healthcare REIT, Inc.
No SEC Form 4 filings for $AHR in the last 30 days.
On May 22, 2026, BofA raised its price target for American Healthcare REIT (AHR) to $67 from $63 and kept a Buy rating, saying it updated REIT models. AHR also announced a May 20 underwritten offering of 14M shares priced at $50.40. In Q1, normalized FFO was 50c (vs 47c consensus) and revenue was $650.77M (below $687.04M).
American Healthcare REIT, Inc. (AHR) has amended and extended its 2026 credit facility, through its operating partnership, executing a second amendment to its existing 2024 credit agreement. This update extends the maturity of revolving loans to April 1, 2030, sets current borrowing capacity at $1.35 billion, and maintains term loans maturing January 19, 2027. Analysts currently rate AHR as a Buy with a $55.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to strong financial trajectory and earnings momentum offset by valuation risk.
American Healthcare REIT (NYSE: AHR) announced it will release its first quarter 2026 earnings on May 7, 2026, after market close, followed by a public conference call and webcast on May 8, 2026, at 10:00 a.m. PT / 1:00 p.m. ET. The company will review its Q1 2026 results, discuss recent events, and conduct a Q&A session. Investors can access the webcast or join via telephone, with a digital replay and full earnings report available on the company's Investor Relations website shortly after the call.
